CARGO Therapeutics Past Earnings Performance
Past criteria checks 0/6
CARGO Therapeutics's earnings have been declining at an average annual rate of -69.8%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-69.8%
Earnings growth rate
50.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -38.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How CARGO Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -154 | 41 | 131 |
| 30 Jun 24 | 0 | -148 | 37 | 117 |
| 31 Mar 24 | 0 | -121 | 29 | 94 |
| 31 Dec 23 | 0 | -98 | 21 | 76 |
| 30 Sep 23 | 0 | -80 | 15 | 58 |
| 30 Jun 23 | 0 | -57 | 10 | 44 |
| 31 Mar 23 | 0 | -46 | 7 | 36 |
| 31 Dec 22 | 0 | -41 | 5 | 29 |
Quality Earnings: CRGX is currently unprofitable.
Growing Profit Margin: CRGX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CRGX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CRGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CRGX has a negative Return on Equity (-38.45%), as it is currently unprofitable.